Live market screen
Commercial Space Company Risk / Opportunity Ranking
Opportunity/risk view across launch, satellites, SAR, earth observation, defense demand, financing events, and execution risk.
Updated June 27, 2026
Opportunity view
Showing rows 1-20 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 1 | ICEYE highstrong | Opp 9 Risk 3 | Thesis: Recent very large funding, high stated valuation, and evidence of expanding sovereign SAR demand support a durable multi-quarter scaling thesis. Why now: On June 9, 2026 ICEYE disclosed a €450 million primary Series F at valuation above €10 billion, with total round size above €1 billion including secondary, and later June context also referenced a €300 million revolving credit facility and additional sovereign satellite demand; those are recent business-state signals for a 1 year+ horizon. Evidence
Caveats: Some support is supporting article context rather than company-specific positive evidence. Several supporting demand/customer references are undated, so recency is uncertain for those claims. |
| 2 | SpaceX highstrong | Opp 9 Risk 4 | Thesis: SpaceX has the strongest evidence-set-backed long-horizon opportunity because it secured multiple large, recent government awards that deepen its role as a core military and civil space infrastructure provider, with contract scope spanning surveillance, communications backbone, and additional NASA crew missions. Why now: The timing is supported by late-May 2026 contract awards: a $2.29 billion Space Force data-network award dated May 26, 2026 and a $4.16 billion Space Force SB-AMTI award dated May 29, 2026/May 30, 2026, plus NASA's plan dated May 24, 2026 to add missions to SpaceX's commercial crew contract, all of which indicate durable backlog expansion and franchise entrenchment over a 1 year+ horizon. Evidence
Caveats: The reviewed sources' available source fields contain no direct positive or negative events for SpaceX; opportunity is inferred from high-materiality neutral facts and article summaries. Ticker mapping is noisy in the reviewed sources: SpaceX is shown with ticker TSLA, which should not be treated as validated public-company identity here. |
| 3 | Apex Space mediummedium | Opp 8 Risk 4 | Thesis: Apex has the strongest opportunity case in this screen because multiple dated June 2026 sources say it raised over $200 million at a $2.3 billion valuation specifically to scale high-rate satellite bus production for proliferated constellations, and a separate dated June 2026 article says Northrop partnered with Apex on space-based interceptors for Golden Dome. Together, these indicate fresh capital, scaling intent, and positioning with government/defense demand vectors over a 1 year+ horizon. Why now: Why now is strong because the key financing evidence is dated June 5, 2026 and the Northrop partnership article is dated June 1, 2026, making both recent within the 90-day recent evidence window and relevant to a 1 year+ scaling thesis. The June 5 financing event is later than the April 16 capacity/context article and therefore better reflects current business state. Evidence
Caveats: Most available evidence is neutral fact or supporting article context, not explicit positive events. Same-day repeated articles around the fundraise are not independent proof beyond corroboration. Some context sources are company-issued or article-level summaries, which are weaker than direct events. |
| 4 | AST SpaceMobile, Inc. highstrong | Opp 8 Risk 5 | Thesis: AST SpaceMobile has strong long-horizon opportunity because it achieved a critical regulatory milestone for a 248-satellite direct-to-device constellation and continues to show ecosystem buildout through operator partnerships and stated constellation scale targets. Why now: The key timing event is the FCC authorization dated April 21, 2026/April 22, 2026 granting authority for up to 248 satellites and direct-to-device service, a milestone that can unlock U.S. commercial and government use cases over a 1 year+ horizon. Later-dated company-site context on June 23, 2026 also says AST has nearly 60 operator partners and targets direct broadband to standard smartphones. Evidence
Caveats: Much of the evidence is company, press-release, or article-context based rather than independent hard performance metrics. The reviewed sources cites a target of 45 to 60 BlueBird satellites by end-2026 in article summary context, but this is not available as a direct structured fact here. |
| 5 | BlackSky Technology Inc. highstrong | Opp 8 Risk 4 | Thesis: BlackSky has the strongest recent opportunity evidence in the screen: a multi-year sole-source $99 million U.S. government IDIQ tied to next-generation Earth observation and space domain awareness development, plus a separate $25 million multi-year assured contract with a major international defense customer. Together these indicate current government demand, product validation, and longer-horizon backlog/ARR support. Why now: The why-now is supported by two dated recent wins inside the recent evidence window: on March 31, 2026 BlackSky said it received a multi-year sole-source $99 million U.S. government IDIQ and initial $2 million funding for advanced large-aperture payload design; on April 22, 2026 it announced a competitive $25 million multi-year assured contract with a major international defense customer and said it had four Gen-3 satellites on orbit and was rapidly deploying Gen-3 capacity while driving up backlog and annual recurring revenue. Evidence
Caveats: The $99 million figure is an IDIQ ceiling, not fully funded revenue at announcement; only an initial $2 million was specifically disclosed. Some corroboration repeats the same underlying announcement and should not be treated as independent evidence |
| 6 | Boeing highstrong | Opp 8 Risk 2 | Thesis: Boeing has the strongest opportunity evidence in this screen because the reviewed sources includes recent company-linked fact evidence that it won a $2 billion U.S. Space Force contract to build two next-generation MUOS communications satellites. The award covers design, development, production, testing, and on-orbit support for a critical military SATCOM network, with launches no earlier than 2031 and 2032 and constellation support through 2035. That is a material, durable space/defense win aligned with the 1 year+ horizon Why now: Why now is strong because the contract was reported on June 23-25, 2026, making it recent within the 90-day recent evidence window, and it represents a fresh, material U.S. defense-space award with multiyear strategic relevance Evidence
Caveats: Some corroborating rows are supporting article context and should not be overcounted as independent confirmation. Program financial benefits may phase in over a long cycle given first delivery timing in 2031. |
| 7 | Capella Space highstrong | Opp 8 Risk 4 | Thesis: Capella Space has the strongest opportunity profile in this screen because the reviewed sources includes a dated, company-specific contract fact showing it won a roughly $49 million SDA contract to build two satellites for a military communications demonstration, adding to evidence that it operates advanced SAR satellite capabilities and serves government and strategic customers. Why now: The April 8, 2026 SDA award is recent within the recent evidence window and is directly relevant to a 1 year+ horizon because it funds spacecraft design and development for a government demonstration program. Later context articles in April-June 2026 continue to depict Capella as an operating SAR platform with defense exposure. Evidence
Caveats: The positive contract evidence is classified as a neutral supporting fact in the reviewed sources, so direction is inferred from the business substance rather than explicit positive polarity labeling. Several contextual articles mention a planned acquisition or subsidiary status, but time-sensitive ownership/public-status interpretations should be treated cautiously because not all such references are direct, dated transaction-closing evidence. For example, and |
| 8 | Impulse Space mediummedium | Opp 8 Risk 4 | Thesis: Impulse Space has the strongest opportunity setup in this screen based on recent, company-linked financing evidence that it raised $500 million in Series D funding to scale production of orbital transfer vehicles, with article context also indicating expansion to support growing commercial and government demand. For a 1 year+ horizon, that capital base can support production scale-up and program execution. Why now: The catalyst is recent and dated: on June 2, 2026/June 3, 2026, Impulse Space disclosed a $500 million Series D and total capital raised above $1 billion, which is highly relevant for a 1 year+ scaling thesis. Evidence
Caveats: Some supportive items are supporting article context and should not be treated as independent confirmation if repeating the same financing announcement. Older commercial contract and government contract references in representative articles are outside the 90-day recent evidence window and therefore not primary recency support here. |
| 9 | Katalyst Space Technologies highstrong | Opp 8 Risk 6 | Thesis: Katalyst Space Technologies has a strong opportunity profile because the reviewed sources show recent evidence of both mission relevance and financing: a NASA Phase III SBIR contract to develop a rescue concept for the Neil Gehrels Swift Observatory and a later June 23, 2026 report that it raised $12 million to develop its NEXUS robotic spacecraft and expand satellite servicing. Why now: Why now is strong because the latest dated evidence on June 23, 2026 adds new capital after the May 29, 2026 NASA-related mission context, supporting a 1 year+ thesis that the company is moving from concept credibility toward funded development in on-orbit servicing. Evidence
Caveats: Part of the positive case comes from company-issued materials and supporting article context rather than independent positive evidence. The May 29, 2026 article includes a dated source date but describes an announcement text beginning 'August 11, 2025'; chronology should therefore be read carefully, with the treated as the recency marker for this retrieved item. Citation |
| 10 | Northrop Grumman Corp mediumstrong | Opp 8 Risk 3 | Thesis: Northrop Grumman has the strongest reviewed sources-supported opportunity profile in this screen due to multiple recent space-defense catalysts: inclusion in the April 8, 2026 Andromeda RG-XX awards, a June 1, 2026 partnership with Apex on Golden Dome space-based interceptors, and a June 22, 2026 $398M Space Force contract for the Enhanced Protected Tactical SATCOM Prototype. Together these support a durable 1 year+ defense-space demand thesis. Why now: The setup is current and cumulative: April 8, 2026 Andromeda participation, June 1, 2026 Golden Dome interceptor partnership, and June 22, 2026 award of a $398M protected satcom contract all fall within the 90-day recent evidence window and point to sustained momentum. Evidence
Caveats: The reviewed sources does not provide direct business impact breakdowns beyond the $398M contract article. Some support is supporting article context rather than dated events. |
| 11 | Observable Space mediummedium | Opp 8 Risk 4 | Thesis: Observable Space has the strongest positive setup in this screen because the reviewed sources contain dated evidence that it raised a $90 million Series A and secured a $94 million U.S. Space Force optical-systems contract, supporting capital availability, customer validation, and potential multi-quarter execution runway. Why now: The timing is favorable because on May 28, 2026 the company was reported to have both closed a $90 million Series A and announced a $94 million U.S. Space Force award, with additional follow-on reporting on June 9, 2026 indicating the contract landed just weeks after the raise, suggesting a recent step-change in funding and government traction for a 1 year+ horizon Evidence
Caveats: Positive direction is inferred from neutral facts plus article summaries; the reviewed sources does not provide explicit positive events. Same-article repeated rows are not independent confirmation. Supporting web-search evidence is context and should be treated below directly cited company evidence. |
| 12 | PLD Space highstrong | Opp 8 Risk 4 | Thesis: PLD Space has recent financing, strategic customer/investor validation, infrastructure investment, and a first commercial launch contract, all of which support a durable launch-scaling thesis over the next year-plus. Why now: The reviewed sources show a sequence of material developments: €180 million Series C on March 4, 2026, €30 million EIB venture debt signed April 7, 2026 and reported May 6, 2026/04-07, first commercial contract reported May 21, 2026, and €35 million Kourou launch-complex investment on June 1, 2026 while MIURA 5 remained on track for a late-2026 first test flight. That is strong state-change evidence for a 1 year+ horizon. Evidence
Caveats: Risk evidence is partly inferred from dependency on future launch milestones rather than a disclosed adverse event. Most support is supporting article context, though the chronology is consistent and material. |
| 13 | Quantum Space mediummedium | Opp 8 Risk 5 | Thesis: Quantum Space has the clearest evidence-backed opportunity profile in this screen: within the recent evidence window it announced a SPAC merger expected to bring substantial capital and public-market access, and later won a Pentagon-funded orbital refueling spacecraft contract built on its Ranger platform. Those developments support a durable 1 year+ thesis around funding access, national-security positioning, and product relevance in on-orbit logistics. Why now: The evidence is recent and sequenced: on June 8, 2026 Quantum Space announced its planned SPAC merger and expected Nasdaq listing under QSPC Evidence
Caveats: Most available evidence is external overlay context rather than first-party positive or negative events. Same-theme repetition across June articles is not independent confirmation. Ticker QSPC is prospective after the expected SPAC close per June 8, 2026 evidence, not confirmed as already trading under that symbol |
| 14 | True Anomaly highstrong | Opp 8 Risk 4 | Thesis: True Anomaly has the strongest opportunity profile in this screen because the reviewed sources contain dated, company-linked evidence that it raised $650 million in Series D financing at a $2.2 billion valuation on April 28, 2026 and was selected by the U.S. Space Force for the Space-Based Interceptor program on May 4, 2026. For a 1 year+ horizon, that combination of fresh capital plus program participation supports scaling, product development, and defense-space positioning. Why now: The recent sequence matters: on April 28, 2026, True Anomaly announced a $650 million Series D at a $2.2 billion valuation, also. Then on May 4, 2026, a dated article said the company was selected by the U.S. Space Force Space Systems Command for the Space-Based Interceptor program. That capital-plus-program sequence is directly relevant to a long-horizon growth thesis. Evidence
Caveats: Most evidence is external overlay context/facts rather than primary data source direct events. Several sources repeat the same April 28 financing story and are not independent confirmation of different events. The company-site article is undated, so recency-sensitive claims from it should be treated cautiously. |
| 15 | Anduril Industries mediummedium | Opp 7 Risk 5 | Thesis: Anduril has a credible 1 year+ opportunity setup from recent participation in major U.S. defense-space programs and fresh financing context. Recent article context says Anduril was among companies awarded Space Force Andromeda contracts for the RG-XX satellite effort on April 8, 2026, and a later article says Anduril raised a $5B Series H round published June 19, 2026, supporting capital availability for scaling in defense-space programs. Why now: The timing is supported by recent 2026 article context around Space Force Andromeda participation and the June 19, 2026 financing context, which together suggest active momentum over the last quarter. Evidence
Caveats: Most evidence is weak context-only article evidence, not direct positive events in the available ranking rows. |
| 16 | Astroscale mediummedium | Opp 7 Risk 4 | Thesis: Astroscale has the clearest 1 year+ opportunity setup in this screen: within the recent evidence window article context shows recent funding support, strategic growth financing for medium-to-long-term expansion, and a shift from demos toward repeatable commercial missions, including defense-related servicing and a 2027 inspection mission pipeline. Why now: Recency is the main reason: on June 22, 2026 SpaceNews said Astroscale was 'working to transition from technology demonstrations to a regular series of missions, bolstered by a recent capital infusion' and saw 'repeatable business opportunities' particularly among defense customers. On May 19, 2026 financing materials said the company would raise 30.6 billion yen to secure medium-to-long-term growth funding 'in anticipation of transitioning to a phase of continuous order acquisition'. On April 6, 2026 Astroscale revealed its ISSA-J1 mission scheduled for launch in 2027. Evidence
Caveats: Most within the recent evidence window evidence is supporting article context, not structured company-specific events; reviewed sources warns supporting article context is weaker than direct event/fact evidence. Same-article repeated weak-context rows are not independent confirmation. Older 2023 and 2025 articles exist in representative articles but fall outside the 90-day recent evidence window for ranking use. |
| 17 | ClearSpace mediummedium | Opp 7 Risk 3 | Thesis: Best opportunity profile in this screen based on multiple dated article-context items showing the company remains active in in-orbit servicing/debris removal, has financing support, is ramping toward ClearSpace-1, and is expanding into defense-adjacent partnership activity. For a 1 year+ horizon, that combination supports a credible strategic growth and market-positioning thesis. Why now: Why now is supported by recent dated context: on June 24, 2026, SpaceNews reported ClearSpace signed an MOU with Shield Space to develop sovereign space defense capabilities for the UK and allies, indicating adjacent market expansion. On May 19, 2026, the company site said it had finalized a EUR 26.7 million Series A and was ramping operations ahead of ClearSpace-1 scheduled to launch in 2026. These dated items fit a 1 year+ horizon because they point to ongoing commercialization and mission preparation. Evidence
Caveats: Most evidence is supporting article context, not direct positive events. The financing article published on May 19, 2026 references January 19, 2023 for the Series A round, so funding recency versus page recency should not be conflated. |
| 18 | Cowboy Space mediummedium | Opp 7 Risk 4 | Thesis: Cowboy Space has the strongest positive evidence in this screen: a large Series B financing at a substantial valuation, explicit plans to build vertically integrated rockets plus orbital data-center infrastructure, and stated hiring/buildout activity. That combination supports a durable 1 year+ strategic opportunity thesis. Why now: Multiple dated articles on May 11, 2026 report Cowboy Space raised $275 million in Series B financing at a $2 billion valuation to build rockets with orbital data-center upper stages, and a TechCrunch article says the company is standing up its own rocket program with a first launch expected before end-2028 Evidence
Caveats: The reviewed sources contain no explicit negative event evidence; risk is inferred from execution complexity and long timeline, not from adverse events. Several supporting rows repeat the same May 11, 2026 financing story and are not independent confirmation. Some supporting article context is undated and should be treated cautiously for recency. |
| 19 | Dawn Aerospace mediummedium | Opp 7 Risk 3 | Thesis: Dawn Aerospace has the strongest opportunity evidence in this screen because a recent dated company article says it closed a $25 million Series B at a $195 million post-money valuation to accelerate global expansion of reusable space transportation. The funding is directly tied to rollout, commercial scaling in the US and Europe, and support for an expanding international customer base, which fits a 1 year+ horizon. Why now: The key catalyst is recent and explicit: on June 16, 2026 the company announced the Series B close and said the proceeds will finance global rollout and scaling of commercial and operational teams in the US and Europe. Evidence
Caveats: Evidence comes from a company-published article, so it is not fully independent. No direct structured positive event row is provided beyond supporting article context. |
| 20 | Eutelsat Communications SA mediummedium | Opp 7 Risk 4 | Thesis: Eutelsat has a strong long-horizon opportunity case from the reviewed sources' membership rationale stating it is supervising a 264-satellite IRIS2 element and won a €350M French defense satellite contract with sovereign LEO capacity. That combines infrastructure scale with government-backed demand. Why now: The reviewed sources' membership rationale cites current program/contract relevance through support articles 2026-04, and: but were not provided in the payload, limiting precise timing narration. Evidence
Caveats: The reviewed sources does not provide for the membership-support article IDs. Opportunity score is tempered by the absence of kept direct evidence in the ranking payload. |
Risk view
Showing rows 121-140 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 121 | Aalyria Technologies mediumweak | Opp 5 Risk 2 | Thesis: The reviewed sources includes no material negative evidence; the main risk is thin grounding because the conclusion relies on one cited contract-related article without available detail or corroboration. Why now: Current relevance is tied to the cited Space Force Golden Dome contract award context in article, though the reviewed sources omits the and representative article details. Caveats: No article is supplied for the cited support article. Opportunity rests on a single contract-related rationale summary. Contract inclusion alone does not reveal contract size, economics, or conversion pace. |
| 122 | Agnikul lowweak | Opp 3 Risk 2 | Thesis: Risk is moderate because the reviewed sources explicitly says it lacks direct, specific evidence of rocket company operations or a funding/contract event for Agnikul itself in the included material, so the opportunity case is not adequately grounded. Why now: The only timing argument is broad strategic sector positioning in Indian spacetech; there is no validated current catalyst in available evidence. Caveats: Phase-2 rationale references: and: but the reviewed sources does not provide or summaries. Sector beneficiary framing is weaker than direct company event/fact evidence. Coverage debug shows zero evidence after recent evidence window. |
| 123 | Antaris Inc. lowweak | Opp 2 Risk 2 | Thesis: Current ranking risk is mostly uncertainty risk: without retained evidence inside the 90-day window, the reviewed sources does not establish whether the referenced programs are progressing, delayed, funded, or commercially material. Why now: There is no retained 90-day evidence in these reviewed sources despite references to evidence in earlier processing. Recency-sensitive conclusions therefore cannot be made from the local reviewed sources. Caveats: Membership rationale references older evidence but no article IDs are provided with accessible summaries in these reviewed sources body. No representative articles or retained evidence are included. Low score reflects evidence absence, not a negative business judgment. |
| 124 | Apogeo Space lowweak | Opp 4 Risk 2 | Thesis: No material adverse evidence is provided, but the reviewed sources does not show contract economics, execution milestones, or customer traction, so commercialization risk remains. Why now: The reviewed sources' membership rationale cites article: for the integration agreement and technical collaboration, but no article or direct evidence are included. Caveats: Evidence is thin and article-level details are missing. Collaboration and integration agreements are weaker than revenue-bearing customer wins. Single-article support limits conviction. |
| 125 | Arctus Aerospace lowweak | Opp 3 Risk 2 | Thesis: The reviewed sources also explicitly says it is unclear whether Arctus is a true space company versus an atmospheric UAV company. That category ambiguity weakens thesis durability for this specific ranking universe, and no adverse company-specific event is otherwise available. Why now: Funding plus ongoing development could matter over a 1 year+ horizon, but there is no retained dated evidence row to confirm timing, financing close date, or development milestone sequence. Caveats: No current evidence is provided for the cited support article in the reviewed sources. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. The positive case relies on phase2 rationale rather than retained direct event/facts. |
| 126 | Argotec lowweak | Opp 1 Risk 2 | Thesis: The main risk is evidentiary opacity: no kept structured positive or negative rows are available after recent evidence window, so business-state, traction, and durability are uncertain. Why now: Why now is weak because the reviewed sources show zero evidence kept within the 90-day recent evidence window for ranking, and the only cited support is an older membership rationale referring to 7 Hawk microsatellites for Italy's IRIDE constellation aboard a SpaceX launch from article: but no article or dated evidence row is provided in the reviewed sources for ranking use. Caveats: No article is provided for the membership support article: so it cannot be cited as a factual ranked-evidence item under the the evidence standard. Coverage debug shows zero evidence after recent evidence window. Private/public status is not used as a filter and is unclear from these reviewed sources. |
| 127 | Astranis lowmedium | Opp 4 Risk 2 | Thesis: The evidence is mostly supporting article context rather than strong company-specific event extraction, so execution and conversion risk remain, but there is no direct adverse evidence available. Why now: Recent dated context within the 90-day recent evidence window points to fresh financing and government program inclusion, both relevant for a 1 year+ horizon: Andromeda context on April 8, 2026 and funding context on June 19, 2026 Evidence
Caveats: Evidence is mainly supporting article context, which is weaker than direct event/fact evidence. An older 2025 article about a 2027 transportation deal exists, but it is outside the recent evidence window and not used as current proof. |
| 128 | Astranis Space Technologies lowweak | Opp 2 Risk 2 | Thesis: There is no direct adverse evidence, but the ranking is constrained by zero retained evidence after recent evidence window and potential duplication concerns in the broader article set. Why now: The current batch retains no representative articles or evidence within the 90-day recent evidence window for Astranis, so the reviewed sources does not provide a current dated catalyst despite the phase-2 rationale. Caveats: No retained evidence after recent evidence window. Phase-2 rationale mentions duplicate article versions; duplicates would not be independent confirmation anyway. |
| 129 | Astrobotic Technology lowweak | Opp 2 Risk 2 | Thesis: No material adverse evidence is available in the reviewed sources, so a negative thesis is unsupported. Why now: The rationale references articles, and: but no corresponding available evidence remains available for direct scoring after recent evidence filtering. Caveats: Lunar lander category fit does not equal thesis attractiveness. Coverage debug shows zero available evidence after recent evidence window. Without direct execution, funding, contract-conversion, or mission-status evidence, scores should remain conservative. |
| 130 | Astrolight UAB lowweak | Opp 2 Risk 2 | Thesis: The key risk is that the only described support is partner context, and the reviewed sources explicitly notes the relation row is context-only, leaving no strong basis for a company-specific positive or negative operating thesis. Why now: There is no usable 'why now' beyond possible strategic relevance to optical communications. The reviewed sources provide no after-recent evidence window evidence to confirm current status. Caveats: Phase-2 rationale references, but the reviewed sources does not include its or article summary. Relations marked context-only cannot be used as counterparty propagation evidence. Coverage debug shows zero evidence after recent evidence window. |
| 131 | Azista Industries Private Limited lowweak | Opp 3 Risk 2 | Thesis: The risk is that technical demonstration does not confirm scalable commercial adoption, contracts, or follow-on funding, and none of those are evidenced in the kept reviewed sources rows. Why now: The only support cited is article in the membership rationale. Because the company coverage report shows zero articles after recent evidence window and zero evidence after recent evidence window, there is no robust timing catalyst beyond the historical demonstration narrative. Caveats: Single-article support only, and not available as active evidence. No direct evidence on customer conversion, regulatory adoption, or funding. Private-company visibility is limited in these reviewed sources. |
| 132 | Azista Space lowweak | Opp 2 Risk 2 | Thesis: Risk is mostly uncertainty from minimal coverage: only one article was considered and zero evidence were available after recent evidence window, so durability, backlog, and execution status are unverified here. Why now: Why now is weak because there is no surviving 90-day evidence row in the reviewed sources to establish recency or momentum. Caveats: Only membership rationale is available; no citeable direct evidence with are provided. Single-article universe increases fragility of inference. |
| 133 | Beijing Guodian High-Tech Technology Co lowweak | Opp 4 Risk 2 | Thesis: No direct adverse evidence is provided in the reviewed sources; main risk is limited visibility into commercialization and scale from the single referenced article. Why now: The implied catalyst is the pilot-program approval, but the reviewed sources provide no retained article summary or timestamped evidence row beyond the membership rationale. Caveats: Phase2 membership rationale references: but the actual summary/evidence are absent. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Opportunity score is restrained because approval alone is described in rationale but not directly evidenced here. |
| 134 | Bellatrix Aerospace lowweak | Opp 3 Risk 2 | Thesis: Risk is primarily execution and verification uncertainty because the reviewed sources have zero available evidence after recent evidence window, so no current milestone, financing, or contract confirmation is available. Why now: Why now is only moderate in theory because propulsion/platform partnerships can matter over a 1-year-plus horizon, but these reviewed sources does not provide recency-anchored evidence after recent evidence window. Caveats: No direct evidence with available for citation. Technology differentiation is only inferred from membership rationale and is not independently corroborated in available evidence. |
| 135 | Blackstar Orbital lowweak | Opp 2 Risk 2 | Thesis: The main risk is evidence quality: the reviewed sources itself says the evidence is mostly partnership context and lacks direct company-specific operating detail, which weakens any durable 1 year+ thesis. There is still no material adverse event available after recent evidence window. Why now: No near-term or durable catalyst can be established from retained evidence because coverage debug shows zero article IDs and zero evidence after recent evidence window. Caveats: No are provided for the cited support articles in the reviewed sources. The reviewed sources explicitly characterizes the evidence as mostly partnership context rather than direct operating detail. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. |
| 136 | Boeing highstrong | Opp 8 Risk 2 | Thesis: Source-specific risk is low because there is no available direct adverse evidence tied to Boeing's space thesis in this screen. The main offset is that the contract contributes to a long-cycle program with delivery beginning in 2031, so near-term financial realization is likely gradual rather than immediate, but that is not a negative event Why now: Why now is strong because the contract was reported on June 23-25, 2026, making it recent within the 90-day recent evidence window, and it represents a fresh, material U.S. defense-space award with multiyear strategic relevance Evidence
Caveats: Some corroborating rows are supporting article context and should not be overcounted as independent confirmation. Program financial benefits may phase in over a long cycle given first delivery timing in 2031. |
| 137 | Brightside Group S.A. lowweak | Opp 2 Risk 2 | Thesis: Risk is modest due to lack of current corroborating evidence rather than any adverse development. The reviewed sources contain no direct negative evidence. Why now: Why now is weak because no representative article or direct evidence survives in the ranking fields after recent evidence window; only membership rationale references without surfaced article content. Caveats: No direct within the recent evidence window evidence is available in ranking fields. Membership rationale alone is weaker than surfaced company-specific event evidence. No negative thesis is supportable from the reviewed sources. |
| 138 | CAS Space lowweak | Opp 2 Risk 2 | Thesis: The same rationale says there is little direct company-specific detail beyond inclusion in that group. Without available direct evidence after recent evidence window, the main risk is thesis fragility and inability to verify the claimed IPO/pre-IPO progression. Why now: There is no verified current catalyst in retained evidence. IPO/pre-IPO framing could matter on a 1 year+ horizon, but recency and milestone state cannot be confirmed here because no dated evidence are available after recent evidence window. Caveats: No are provided for the cited support articles in the reviewed sources. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. IPO/pre-IPO mention is only in reviewed sources rationale, not in retained direct evidence. |
| 139 | Casimir Inc. lowweak | Opp 1 Risk 2 | Thesis: Casimir carries above-peer evidence risk in this screen because the sole cited support is described in the phase2 rationale as blog commentary, and the business fit to the target cohort is explicitly questioned. That weak grounding raises the risk of over-interpreting the financing mention. Why now: There is no available article summary or evidence row after recent evidence window, so the only 'why now' is the uncitable phase2 statement about a seed round referenced by article id: without. Caveats: The reviewed sources itself says the support article is blog commentary, weakening source quality. No citable or summary is provided for the referenced article id No evidence were available after recent evidence window in the served reviewed sources. |
| 140 | constellr mediummedium | Opp 5 Risk 2 | Thesis: Risk remains moderate because the evidence is still supporting article context rather than direct company disclosures about backlog, margins, or contracted demand, and no negative evidence is available. Execution risk remains around converting first-launch and funding momentum into durable commercial scale. Why now: Why now is relatively strongest here because the retained evidence is within the 90-day recent evidence window and dated April 16, 2026, summarizing recent business-state milestones including a first satellite launch in January 2025 and a Series A closed in February 2026. Evidence
Caveats: Evidence is external article context, not a direct company filing or contract announcement. |